Vir Biotechnology stock hits 52-week high at 11.96 USD

Vir Biotechnology Inc. has achieved a noteworthy milestone, with its stock reaching a 52-week high of $11.96. The biotech company, valued at $2 billion, is trading close to its VIP InvestingPro Fair Value, indicating the stock is currently priced appropriately. This accomplishment highlights a remarkable year for the company, as its stock value has surged by 104.14% over the past year.

InvestingPro Tips reveal that VIR has provided substantial returns over the last year and is presently trading near its 52-week high. Potential investors should take note of the stock's volatility, as it exhibits a beta of 1.59. This surge in stock price signifies positive investor sentiment and may be influenced by recent developments within Vir Biotechnology's operations or market conditions.

As the company navigates the competitive biotechnology sector, this 52-week high represents a significant point of progress and growth. In recent financial news, Vir Biotechnology reported impressive results for the second quarter of 2026, driven by a substantial collaboration payment from Astellas. This payment contributed to the company's net income of $80.1 million, a sharp improvement from the previous year's loss, and boosted cash reserves to over $1 billion.

Analysts have also taken notice, with H.C. Wainwright raising its price target for Vir Biotechnology to $22 from $20 and maintaining a Buy rating. This upgrade is attributed to the progress in the VIR-5500 program for prostate cancer, as well as favorable safety and tolerability profiles from the monotherapy dose escalation phase.

Raymond James also reinforced its Strong Buy rating and adjusted its price target to $19, following promising clinical trial results from a competitor in hepatitis delta virus infection. Furthermore, H.C. Wainwright retained its Buy rating, now targeting $20, highlighting advancements in Vir Biotechnology's hepatitis D virus treatment programs.

These developments underscore the company's ongoing success in clinical trials and financial well-being.